A MODEL TO PREDICT COSTS AND OUTCOMES ASSOCIATED WITH HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE OR HEART FAILURE
Author(s)
Bennett H1, Palaka E2, Ayoubkhani D1, Evans M3, McEwan P1, Bergenheim K4, Kim K5, Grandy S6
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2AstraZeneca, Cambridge, UK, 3University Hospital Llandough, Cardiff, UK, 4AstraZeneca, Gothenburg, Sweden, 5AstraZeneca, Södertälje, Sweden, 6Astrazeneca Phamaceuticals , LP, Gaithersburg, MD, USA
OBJECTIVES: Hyperkalaemia (HK) increases the risk of major adverse cardiovascular events (MACE) and mortality. Patients with heart failure (HF) or chronic kidney disease (CKD) are susceptible to HK due to impaired renal function, older age, comorbidities, and concomitant medications. This study aimed to develop a novel cost-effectiveness model to estimate cost and health outcomes associated with effective HK management in HF or CKD. METHODS: A lifetime patient-level simulation was developed in Microsoft Excel. Disease progression was modelled in HF via progression through New York Heart Association (NYHA) classes and in CKD via continuous estimated glomerular filtration rate (eGFR) decline, leading to end-stage renal disease (ESRD). Time-dependent potassium (K+) trajectories were simulated utilising mixed-effects regression equations and linked to mortality, hospitalisation, MACE and changes in renin-angiotensin-aldosterone system inhibitor use via published risk ratios. Two hypothetical scenarios were evaluated from a UK payer perspective, independent of long-term K+ management costs: lifetime maintenance of normokalaemia (NK) compared to fluctuating K+ levels resulting in HK rates consistent with clinical practice. Published utilities and disease costs (2015) were applied and discounted at 3.5%. RESULTS: In patients aged 60 at baseline with CKD (eGFR=50 ml/min/1.73m) predicted life expectancy (LE), quality-adjusted life years (QALYs) and total costs (TC) were 9.0 years, 6.7 QALYs and £69,606 in the NK group compared to 8.6 years, 6.3 QALYs and £65,231 in the HK group. Increased survival to ESRD drove higher estimated TC in the NK group. In patients aged 60 at baseline with HF (NYHA III) predicted LE, QALYs and TC were 7.8 years, 5.6 QALYs and £7,881 in the NK group and 5.9 years, 4.3 QALYs and £6,374 in the HK group, respectively. CONCLUSIONS: Optimising K+ management in CKD and HF patients has the potential to increase LE and QALYs, while influencing direct healthcare expenditure and allowing for an efficient use of resources.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PHP86
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders, Urinary/Kidney Disorders